The supplement that makes Continual-G possible didn't appear overnight. It took a New Zealand biochemist, two decades of molecular research, and a 2017 clinical paper to get from 'what if' to 'what works'. Here's the story.

Most supplements are born in a marketing meeting. Someone sees a trending ingredient, puts it in a capsule, and calls it revolutionary. The story of Glyteine® is different. It began with a genuine scientific question — and took more than twenty years to answer it in a form that could reach you as a supplement.

The Question: Why Can't You Just Raise Glutathione?

Dr. Wallace Bridge is a biochemist from New Zealand who spent the better part of his career asking a deceptively simple question: glutathione is the most important antioxidant in the human cell — why is it so hard to raise intracellular levels with supplementation? The oral route doesn't work well (digestion destroys it). The IV route misses the cell interior. NAC and cysteine hit the GCL bottleneck. Every strategy researchers tried ran into one of these three walls.

His insight — the one that changed the framework — was this: why are we trying to deliver the finished product, or upstream raw materials that hit the bottleneck? What if we supply the cell with exactly what GCL makes — the direct input to step two? The cell already has everything it needs for step two. It just needs the substrate.

 

 

Why It Took So Long

Good science takes time. The concept of γ-glutamylcysteine as a glutathione precursor was not new — the molecule appears in standard biochemistry textbooks because it's what the GCL enzyme naturally makes. What was new was asking: can it be stabilised for oral delivery? Does the cell have a transporter for it in a supplementation context? And — most importantly — does it actually raise intracellular (not just plasma) glutathione in living humans?

Each of these questions required years of research to answer properly. The stabilisation problem required formulation science. The transporter question required cell biology. The clinical question required human trials with HPLC measurement of intracellular glutathione — a technically demanding measurement that many supplement studies skip in favour of easier (but less meaningful) plasma measurements. The Zarka & Bridge team did the hard version. That's why the paper matters.

Why SkinBB Chose This Molecule

When SkinBB — Skin Beyond Borders — was building its Unique innovative platform, the question was the same question it asks about everything on the platform: what does the best published science actually support? Not what's trending. Not what's cheap to manufacture. What does the evidence say? The evidence said Glyteine®. The research arc pointed clearly to γ-glutamylcysteine as the most efficient, most direct, best-evidenced route to elevated intracellular glutathione.

 

 

No Indian brand had brought it to market because it requires understanding a 20-year research arc, navigating FSSAI approval for a novel ingredient, and building the educational infrastructure to explain it to consumers. SkinBB was built for exactly this. Continual-G is what happens when a platform takes the research seriously.

The Bottom Line

Glyteine® is not a quick supplement invention. It's the result of 20+ years of biochemical research asking the right question: if the cell already knows how to make glutathione, why not give it exactly the molecule it needs for step two — bypassing the bottleneck at step one? The answer, published in 2017 and measured directly in human cells, is a 53% intracellular rise in 90 minutes. That's the science. That's the story. That's the molecule in Continual-G — available exclusively on SkinBB, India.

 

 

Your Questions, Answered

1. Who invented Glyteine®?

Dr. Wallace Bridge, a New Zealand biochemist, is the primary researcher behind Glyteine® as a commercialisable supplement form. The landmark study is Zarka & Bridge, Redox Biology, 2017 (PMID: 28131081).

 

2. Is there more research planned for Glyteine®?

The 2017 study is a pilot trial. Larger confirmatory randomised controlled trials would strengthen the evidence base — and the scientific community is aware of Glyteine® as a promising area. SkinBB communicates the current state of evidence accurately, including the pilot nature of the primary study.

 

3. Why hasn't the Indian supplement industry picked up Glyteine® before SkinBB?

Bringing a novel ingredient to India requires FSSAI registration for an unusual food supplement, supply chain establishment, and — for something this technical — a platform capable of educating consumers accurately. Most supplement brands prioritise speed and trend alignment. SkinBB prioritised scientific accuracy.

 

4. Is Glyteine® the same as NAC?

No. NAC (N-Acetylcysteine) provides cysteine to step one of glutathione synthesis — it still passes through the GCL bottleneck. Glyteine® is γ-glutamylcysteine — the output of step one, input to step two. One bypasses the bottleneck; the other doesn't.

 

5. Will newer research change the picture for Glyteine®?

Science evolves. SkinBB's commitment is to communicate evidence accurately as it develops. The current published data — mechanism, intracellular evidence, safety profile — is the basis for Continual-G. If new studies emerge, SkinBB will update the platform accordingly.